C18 Ceramide-d7 (d18:1-d7/18:0)
(Synonyms: C18 Ceramide-d7) 目录号 : GC46988An internal standard for the quantification of C18 ceramide
Cas No.:1840942-14-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
C18 Ceramide-d7 is intended for use as an internal standard for the quantification of C18 ceramide by GC- or LC-MS. C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.[1] Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.[2] It is selectively down-regulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.[3]
Reference:
[1].Mizutani, Y., Kihara, A., and Igarashi, Y.Mammalian Lass6 and its related family members regulate synthesis of specific ceramidesBiochem J.390(Pt. 1)263-271(2005)
[2].Koybasi, S., Senkal, C.E., Sundararaj, K., et al.Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomasJ. Biol. Chem.279(43)44311-44319(2004)
[3].Bergman, B.C., Brozinick, J.T., Strauss, A., et al.Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humansDiabetologia59(3)785-791(2016)
| Cas No. | 1840942-14-4 | SDF | |
| 别名 | C18 Ceramide-d7 | ||
| 化学名 | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-15,15,16,16,17,17,17-d7]-octadecanamide | ||
| Canonical SMILES | OC[C@H](NC(CCCCCCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H] | ||
| 分子式 | C36H64D7NO3 | 分子量 | 573 |
| 溶解度 | DMF: 0.15 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7452 mL | 8.726 mL | 17.452 mL |
| 5 mM | 0.349 mL | 1.7452 mL | 3.4904 mL |
| 10 mM | 0.1745 mL | 0.8726 mL | 1.7452 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。